ReviewMedicine2025
Pathogenic mechanisms and treatment advances in proliferative vitreoretinopathy: A review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Post-vitrectomy hypotony: mechanisms, risk factors and management strategies.International ophthalmology · 2026Review
- A clinical prediction tool for ocular hypertension following silicone oil tamponade in rhegmatogenous retinal detachment.BMC ophthalmology · 2026Article
- Differentially expressed genes in rabbits with traumatic proliferative vitreoretinopathy based on high-throughput sequencing.International journal of ophthalmology · 2026Article
- Evaluation of serum YKL-40 and Galectin-3 as predictive biomarkers for proliferative vitreoretinopathy in rhegmatogenous retinal detachment: a prospective comparative study.BMC ophthalmology · 2025Article
- Nanotechnology-Based Delivery Systems and Retinal Pigment Epithelium: Advances, Targeting Approaches, and Translational Challenges.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Proliferative vitreoretinopathy (PVR) is the most common cause of repair failure in rhegmatogenous retinal detachment and a severe complication of posterior segment penetrating injuries. The pathogenesis of PVR is complex, and there is currently no ideal therapeutic drug in clinical practice. Surgical intervention involves the removal of proliferative membranes to relieve traction on the retina, but it carries a certain postoperative recurrence rate. This review provides an overview of the pathogenesis and treatment strategies for PVR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.